Invention Grant
- Patent Title: Dendritic-cell-targeted peptide, fusion peptide utilizing said peptide, and vaccine utilizing said fusion peptide
-
Application No.: US16335625Application Date: 2017-09-21
-
Publication No.: US11186618B2Publication Date: 2021-11-30
- Inventor: Yasuo Yoshioka
- Applicant: The Research Foundation for Microbial Diseases of Osaka University
- Applicant Address: JP Suita
- Assignee: The Research Foundation for Microbial Diseases of Osaka University
- Current Assignee: The Research Foundation for Microbial Diseases of Osaka University
- Current Assignee Address: JP Suita
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: JPJP2016-183942 20160921,JPJP2017-129202 20170630
- International Application: PCT/JP2017/034069 WO 20170921
- International Announcement: WO2018/056351 WO 20180329
- Main IPC: C07K14/415
- IPC: C07K14/415 ; A61K9/00 ; C07K14/36 ; C07K14/315 ; C07K19/00 ; A61P37/04 ; C07K7/06 ; A61K47/50 ; A61K39/00 ; C12P21/02 ; C12N15/09

Abstract:
The purpose of the present invention is to provide a peptide that is capable of efficiently delivering an antigen to dendritic cells and improving the vaccine effects of the antigen. A peptide that has at least one motif sequence comprising the amino acid sequence of sequence listing 1, or an amino acid sequence comprising the aforementioned amino acid sequence, but in which a mutation has been induced in the amino acid residue at the first and/or second position of the amino acid sequence, is bound to an antigen protein or an antigen peptide to efficiently deliver the antigen protein or antigen peptide to dendritic cells, allowing for significantly superior vaccine effects to be exhibited.
Public/Granted literature
Information query